5-benzyloxy-3-dimethylaminoethyl-1-phenylindole | 297751-70-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-benzyloxy-3-dimethylaminoethyl-1-phenylindole
• 英文别名: N,N-dimethyl 2-(1-benzenesulphonyl-5-benzyloxy-1H-indol-3-yl)ethylamine；2-[1-(benzenesulfonyl)-5-phenylmethoxyindol-3-yl]-N,N-dimethylethanamine
• CAS: 297751-70-3
• 化学式: C₂₅H₂₆N₂O₃S
• 分子量: 434.559
• InChiKey: PLQFOHQKYPNKGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  59.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-benzyloxy-3-dimethylaminoethyl-1-phenylindole 在 catalyst 、 氢氧化钯 Ammonia methanol dichloromethane 、 silica gel 、 乙醚 作用下， 以 乙醇 为溶剂， 反应 7.0h， 以to give the title compound as a crystalline solid after trituration with diethyl ether (30 ml)的产率得到N,N-dimethyl 2-(1-benzenesulphonyl-5-hydroxy-1H-indol-3-yl)ethylamine
  参考文献：
  名称：

  Indole and indoline derivatives as 5-HT6 selective ligands

  摘要：

  公开了三类吲哚和吲哚啉衍生物作为选择性5-HT6受体配体，因此对于治疗或预防中枢神经系统疾病，包括阿尔茨海默病、帕金森病、精神分裂症、抑郁症和焦虑症具有价值。其中一类为1-取代-4-(&ohgr;-N,N-二烷基-氨基烷基)吲哚，被认为是新型化合物。

  公开号：

  US06187805B1
• 作为产物：
  描述：

  N,N-二甲基-5-(苄氧基)-1H-吲哚-3-乙胺 、 苯磺酰氯 在 四丁基硫酸氢铵 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 5-benzyloxy-3-dimethylaminoethyl-1-phenylindole
  参考文献：
  名称：

  N-Arylsulfonylindole Derivatives as Serotonin 5-HT₆ Receptor Ligands

  摘要：

  A series of N-1-arylsulfonyltryptamines were found to be potent ligands of the human serotonin 5-HT6 receptor with the 5-methoxy-1-benzenesulfonyl analogue (19) having the highest affinity. Additionally, it was discovered that a group such as 3-(3-methoxybenzyl)-1,2,4-oxadiazol-5-yI in the 2-position of the indole ring (43) can replace the arylsulfonyl substituent in the 1-position with no loss of affinity. This suggested that the binding conformation of the aminoethyl side chain at this receptor was toward the 4-position of the indole ring and was supported by the fact that the 4-(aminoethyl)indoles (45) also displayed high affinity, as did the conformationally rigid 1,3,4,5-tetrahydrobenz[c,d]indole (49). Molecular modeling showed that 19, 43, and 45 all had low-energy conformers that overlaid well onto 49. Both 19 and 49 had good selectivity over other serotonin receptors tested, with 49 also showing excellent selectivity over all dopamine receptors. In a functional adenylate cyclase stimulation assay, 19 and 49 had no agonist activity, whereas 45 behaved as a partial agonist. Finally, it was shown that 19 had good activity in the 5-HT2A centrally mediated mescaline-induced head twitch assay, which implies that it is brain-penetrant.

  DOI：

  10.1021/jm010943m

文献信息

• Use
  申请人：——

  公开号：US20030139424A1

  公开（公告）日：2003-07-24

  The invention provides a method of treatment or prophylaxis of obesity or for the reduction of food intake, comprising administering to a patient in need of such treatment a therapeutically effective amount of an indole or indoline derivative of Formula I, II or III: 1 wherein the substituents are as described in the specification.

  本发明提供了一种治疗或预防肥胖或减少食物摄入的方法，包括向需要此类治疗的患者给予公式I、II或III的吲哚或吲哚啉衍生物的治疗有效量：1其中取代基如说明书所述。
• Lee; Rangisetty; Dukat, Medicinal Chemistry Research, 2000, vol. 10, # 4, p. 230 - 242
  作者：Lee、Rangisetty、Dukat、Slassi、Maclean、Lee、Glennon

  DOI：——

  日期：——
• USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE
  申请人：BIOVITRUM AB

  公开号：EP1438045A1

  公开（公告）日：2004-07-21
• US6187805B1
  申请人：——

  公开号：US6187805B1

  公开（公告）日：2001-02-13
• [EN] USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE<br/>[FR] UTILISATION DE DERIVES D'INDOLE ET D'INDOLINE POUR LE TRAITEMENT DE L'OBESITE OU LA REDUCTION DE L'APPORT ALIMENTAIRE
  申请人：BIOVITRUM AB

  公开号：WO2003035061A1

  公开（公告）日：2003-05-01

  The invention provides the use of an indole or indoline derivative of Formula, II or III: wherein the substituents are as described in the specification; in the manufacture of a medicament for the treatment or prophylaxis of obesity or for the reduction of food intake. The invention also relates to the use of indole or indoline derivatives of Formula I, II or III for improving the bodily appearance of a mammal by causing loss of weight, as well as cosmetic compositions containing said compounds.